R&D Trends

ALS TDI, Gladstone Institutes to discover potential ALS treatments

Wednesday, December 5, 2012 09:44 AM

The ALS Therapy Development Institute (ALS TDI), aimed at developing effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS), and the Gladstone Institutes, a nonprofit biomedical-research organization, have formed a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.

More... »

Synthetic completes acquisition of C. difficile infectious disease program

Tuesday, December 4, 2012 08:00 AM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic biologics and innovative medicines for serious infections and diseases, has closed the previously announced deal with Prev AbR and acquired a series of beta-lactamase compounds (P1A, P2A and P3A) and related assets targeting the prevention of Clostridium difficile (C. diff) infection.

More... »

Hovione, Solvias collaborate to provide for improved drug solubility

Monday, December 3, 2012 10:54 AM

Hovione, a global group dedicated to the cGMP development and manufacture of APIs, and Solvia, a privately held solutions provider based in Basel, Switzerland, have established a collaboration focused on the development and GMP supply of pharmaceutical co-crystals.

More... »

Selecta, Sanofi to develop antigen-specific immunotherapies for life-threatening allergies

Friday, November 30, 2012 10:55 AM

Selecta Biosciences, a Watertown, Mass.-based clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, has entered into a strategic global collaboration with global healthcare company Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.

More... »

Curis licensed IAP inhibitor GDC-0917 from Genentech

Wednesday, November 28, 2012 01:54 PM

Curis, a Lexington, Mass.-based drug development company focused on targeted small molecule drug candidates for cancer treatment, has licensed from San Francisco-based Genentech, a member of the Roche Group, exclusive worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins.

More... »

Roche, Broad Institute to identify novel uses for failed phase II compounds

Wednesday, November 28, 2012 01:39 PM

Roche, through its Translational and Clinical Research Center, and the Broad Institute, a biomedical and genomic research center based in Cambridge, Mass., have signed a multi-year collaboration designed to identify novel indications for promising development-stage compounds using the Broad Institute's platforms of screening technologies.

More... »

IntelliCell BioSciences inks research agreement with Rutgers’ N.J. Center for Biomaterials

Wednesday, November 28, 2012 11:16 AM

IntelliCell BioSciences, a regenerative medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs, has entered a sponsored research agreement with the New Jersey Center for Biomaterials at Rutgers, the state university of New Jersey.

More... »

NEOMED Institute aims to renew biopharmaceutical research in Québec

Tuesday, November 27, 2012 11:33 AM

AstraZeneca Canada and Pfizer Canada are forming a partnership with the Québec government to create the NEOMED Institute, a new kind of life sciences research center. A total of $100 million will be invested to establish and support the research center over five years.

More... »

Shire, Boston Children's Hospital collaborate on rare pediatric diseases

Tuesday, November 20, 2012 10:54 AM

Boston Children’s Hospital and Shire, a specialty biopharmaceutical company based in Ireland, have signed a three-year, broad research collaboration in rare diseases.

More... »

NeuroVive, Sihuan Pharma collaborate on CicloMulsion and NeuroSTAT in China

Tuesday, November 20, 2012 10:25 AM

NeuroVive, a mitochondrial medicine company based in Sweden, has signed a collaboration agreement with Sihuan Pharmaceutical Holdings Group, based in China, for the development and commercialization of NeuroVive's most clinically advanced products CicloMulsion and NeuroSTAT in China.

More... »